Corgenix, in the news recently for its Ebola virus test, will sell itself to a competitor based in Germany for about $16 million. The news comes 5 months after the Denver company revealed it might seek to become an M&A target, in part, to reduce costs and boost efficiency and market reach.
AbbVie's waiting for FDA approval on a hepatitis C combo therapy. OraSure makes a rapid test to detect the virus. And professional truck drivers in the U.S. are more than 5 times as likely as other Americans to have it.
Seventh Sense Biosystems has been quiet these last several months. But now the maker of painless blood collection and diagnostic tech is making some noise, having scored a healthy new round of venture financing.
This summer, venture investment trends have given the medical diagnostics industry reason for at least a little optimism.
Roche's Ventana Medical Systems is linking up with Arizona State University to launch a diagnostics-focused master's degree professional program at the school.
Cambridge, U.K.-based Lab21, which focuses on personalized medicine and clinical diagnostics, plans to become a subsidiary of Paris-based Novacyt, which makes cytology diagnostic tests and tools for various cancers.
FDA officials approved the Georgia company's gene-based test to determine red blood cell types during transfusions.
Seattle's Adaptive Biotechnologies has pulled in $105 million from Viking Global Investors to finish off combined Series C and D rounds. The cash infusion will expand the commercial reach of the company's immunosequencing tech to help diagnose and treat cancer, infectious diseases and autoimmune disorders.
Maryland's Diagnostic Biochips is pursuing a $1.5 million round of angel funding to advance development of a microchip brain implant that would be more precise than an MRI in gathering diagnostic data and less invasive than a blood test.
Two of the biggest players in Brazil's diagnostics industry are likely to confront major changes in the coming months--both worth noting as global competitors seek to enter one of the largest emerging markets around.